SYK:NYE-Stryker Corporation (USD)

EQUITY | Medical Devices | New York Stock Exchange

Last Closing

USD 337.25

Change

+5.23 (+1.58)%

Market Cap

USD 41.39B

Volume

1.01M

Analyst Target

USD 217.70
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Stryker Corp is a medical technology company. The Company offers medical technologies, including reconstructive, medical and surgical, and neurotechnology and spine products.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-05 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
ABT Abbott Laboratories

+0.41 (+0.37%)

USD 195.27B
MDT Medtronic PLC

+0.49 (+0.56%)

USD 114.31B
STE STERIS plc

-1.84 (-0.79%)

USD 23.57B
ZBH Zimmer Biomet Holdings Inc

+0.49 (+0.47%)

USD 22.04B
SNN Smith & Nephew SNATS Inc

-0.13 (-0.43%)

USD 13.32B
SNNUF Smith & Nephew plc

N/A

USD 13.18B
GMED Globus Medical

+0.62 (+0.89%)

USD 9.55B
BIO Bio-Rad Laboratories Inc

+6.61 (+1.96%)

USD 9.53B
BIO-B Bio-Rad Laboratories Inc

N/A

USD 9.38B
PEN Penumbra Inc

-0.26 (-0.13%)

USD 7.80B

ETFs Containing SYK

CIB0:XETRA VanEck Bionic Engineering.. 10.43 % 0.00 %

+0.11 (+0.21%)

USD 6.28M
UMDV:SW iShares US Medical Device.. 10.25 % 0.00 %

N/A

N/A
CYBG:LSE VanEck Bionic Engineering.. 9.94 % 0.00 %

+0.08 (+0.21%)

N/A
JGRW Trust For Professional Ma.. 5.47 % 0.00 %

+0.06 (+0.21%)

N/A
HHL-U:CA Harvest Healthcare Leader.. 5.09 % 0.00 %

N/A

N/A
HHL-B:CA Harvest Healthcare Leader.. 5.09 % 0.00 %

N/A

N/A
MHCD:CA Middlefield Healthcare Di.. 3.90 % 0.00 %

+0.02 (+0.21%)

CAD 0.16B
DRUP GraniteShares ETF Trust -.. 2.55 % 0.00 %

+0.68 (+0.21%)

USD 0.06B
CWS AdvisorShares Focused Equ.. 0.00 % 0.68 %

+0.23 (+0.21%)

USD 0.17B
IHI iShares U.S. Medical Devi.. 0.00 % 0.43 %

+0.23 (+0.21%)

N/A
LNGR 0.00 % 0.50 %

N/A

N/A
XSFD:LSE Xtrackers S&P Select Fron.. 0.00 % 0.00 %

+0.08 (+0.21%)

USD 0.09B
XSFR:LSE Xtrackers S&P Select Fron.. 0.00 % 0.00 %

+8.75 (+0.21%)

USD 0.09B
GOAI:PA Amundi Stoxx Global Artif.. 0.00 % 0.00 %

+0.62 (+0.21%)

USD 0.87B
GOAI:F Amundi Index Solutions - .. 0.00 % 0.00 %

N/A

N/A
DX2Z:XETRA Xtrackers - S&P Select Fr.. 0.00 % 0.00 %

+0.27 (+0.21%)

USD 0.10B
GOAI:XETRA Amundi Stoxx Global Artif.. 0.00 % 0.00 %

+0.86 (+0.21%)

USD 0.98B
TACE 0.00 % 0.00 %

N/A

N/A
AGNG Global X Aging Population.. 0.00 % 0.00 %

+0.16 (+0.21%)

USD 0.06B

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 12.62% 70% C- 80% B-
Dividend Return 0.53% 57% F 12% F
Total Return 13.15% 70% C- 77% C+
Trailing 12 Months  
Capital Gain 14.61% 71% C- 70% C-
Dividend Return 1.07% 57% F 14% F
Total Return 15.68% 71% C- 65% D
Trailing 5 Years  
Capital Gain 61.70% 80% B- 79% B-
Dividend Return 6.48% 50% F 21% F
Total Return 68.19% 84% B 78% C+
Average Annual (5 Year Horizon)  
Capital Gain 13.09% 74% C 76% C+
Dividend Return 14.24% 77% C+ 74% C
Total Return 1.15% 50% F 27% F
Risk Return Profile  
Volatility (Standard Deviation) 21.10% 84% B 50% F
Risk Adjusted Return 67.49% 97% N/A 86% B+
Market Capitalization 41.39B 97% N/A 98% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Devices) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 25.40 70% 16%
Price/Book Ratio 7.00 31% 12%
Price / Cash Flow Ratio 34.08 24% 7%
Price/Free Cash Flow Ratio 28.39 15% 8%
Management Effectiveness  
Return on Equity 18.64% 97% 80%
Return on Invested Capital 11.04% 91% 68%
Return on Assets 7.23% 94% 84%
Debt to Equity Ratio 58.63% 30% 55%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.